Request for Comment Exempt Scheduling Changes

Comment Period Ends: March 30, 2023

Action: Scheduling of chemicals in Schedule I and conforming schedules to federal

scheduling July 7, 2022 – February 3, 2023

Promulgating

Board: Board of Pharmacy

Regulatory Coordinator: Erin Barrett

(804) 367-4688

erin.barrett@dhp.virginia.gov

Agency Contact: Caroline Juran

Executive Director (804) 367-4456

caroline.juran@dhp.virginia.gov

Contact Address: Department of Health Professions

9960 Mayland Drive

Suite 300

Richmond, VA 23233

Chapter Affected:

18VAC110 - 20: Regulations Governing the Practice of Pharmacy

Statutory Authority: Virginia Code § 54.1-3434

Public Hearing Date 3/30/2023

Public Hearing Time 9:05 a.m.

1. Pursuant to article § 54.1-3443(D), The Virginia Department of Forensic Science (DFS) has identified five (5) compounds for recommended inclusion into the Code of Virginia.

The following compounds are classified as synthetic opioids. Compounds of this type have been placed in Schedule I (§ 54.1-3446(1)) in previous legislative sessions.

- N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide (other names: para-fluoro valeryl fentanyl, para-fluoro pentanoyl fentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.
- N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (other name: parafluoroacetyl fentanyl), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.

- Based on their chemical structures, the following compounds are expected to have hallucinogenic properties. Compounds of this type have been placed in Schedule I (§ 54.1-3446(3)) in previous legislative sessions.
- 1-[1-(3-fluorophenyl)cyclohexyl]piperidine (other names: 3-fluoro Phencyclidine, 3F-PCP), its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
- 2-(ethylamino)-2-(2-fluorophenyl)-cyclohexanone (other names: 2-fluoro-2-oxo PCE, 2-fluoro NENDCK), its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

The following compound is classified as a central nervous system stimulant. Compounds of this type have been placed in Schedule I (§ 54.1-3446(5)) in previous legislative sessions.

• 2-(3-chlorophenyl)-3-methylmorpholine (other name: 3-chlorophenmetrazine), its salts, isomers (optical, position, and geometric), and salts of isomers.

2. Pursuant to article § 54.1-3443(E), the following drugs will be placed in Schedule I to conform with federal scheduling actions taken from July 7, 2022 to February 3, 2023:

- N-methyl-1-(thiophen-2-yl)propan-2-amine (other name: methiopropamine)
- N -phenyl- N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate (other name: mesocarb)
- 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol (other name: zipeprol)
- 7-[(10,11-dihydro-5 H -dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid (other name: amineptine)

Pursuant to article § 54.1-3443(E), the following drug will be removed from Schedule IV to conform with federal scheduling actions taken from July 7, 2022 to February 3, 2023:

Fenfluramine